# Oryzon Genomics S.A. > Oryzon Genomics S.A. (BME:ORY, OTC PINK:ORYZF) announcements published on FAQSIR. AI-generated content. Paid-for issuer communication. Not investment advice. canonical: https://faqsir.com/company/oryzon-genomics-sa generated_at: 2026-10-21T09:49:00+00:00 ## Company - Name: Oryzon Genomics S.A. - Listings: BME:ORY, OTC PINK:ORYZF - Also known as: ORYZON, Oryzon, Oryzon Genomics, Oryzon Genomics, S.A. - Website: https://www.oryzon.com/en ## Disclosure - AI-generated content: This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording. - Unpaid evaluation: The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage. - Not investment advice: This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance. - Grounding: Content is generated from the company's published announcements. - Disclosure version: 2026.09.3 ## Endpoints - [Company hub](https://faqsir.com/company/oryzon-genomics-sa): the Oryzon Genomics S.A. announcements listed below, as a page - [Latest announcement](https://faqsir.com/company/oryzon-genomics-sa/latest): redirects to the newest release, or to the hub when there is no recent one - [Atom feed](https://faqsir.com/company/oryzon-genomics-sa/feed): the latest 50 releases, as Atom - [JSON feed](https://faqsir.com/company/oryzon-genomics-sa/feed.json): the latest 50 releases, as JSON Feed 1.1 - [Site-wide llms.txt](https://faqsir.com/llms.txt): what this site publishes beyond this issuer ## Releases Every announcement this hub lists: 25 announcements, newest first. Each URL is that release's canonical URL. - 2026-09-28 — [Oryzon receives EMA authorisation to initiate HOPE-2 Phase IIa study in PMS](https://faqsir.com/company/oryzon-genomics-sa/oryzon-receives-ema-authorisation-to-initiate-hope-2-phase-iia-study-in-pms): Oryzon Genomics has received European Medicines Agency authorisation to initiate HOPE-2, a Phase IIa study evaluating vafidemstat in adults with Phelan-McDermid Syndrome. - 2026-08-31 — [Oryzon reports U.S. Notice of Allowance for iadademstat-gilteritinib patent application](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-us-notice-of-allowance-for-iadademstat-gilteritinib-patent-application): Oryzon Genomics said the USPTO issued a Notice of Allowance for a U.S. patent application covering iadademstat combinations with gilteritinib in myeloid cancers, including AML. - 2026-07-27 — [Oryzon reports first-half 2026 results alongside clinical and financing updates](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-first-half-2026-results-alongside-clinical-and-financing-updates): Oryzon Genomics reported financial results for the quarter and six months ended June 30, 2026, alongside updates on its AML, mental health and neurological disorder programmes. - 2026-07-08 — [Oryzon reports U.S. patent grant covering vafidemstat in non-aggressive BPD symptoms](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-us-patent-grant-covering-vafidemstat-in-non-aggressive-bpd-symptoms): Oryzon Genomics has reported a U.S. patent grant covering the use of vafidemstat and other LSD1 inhibitors for non-aggressive symptoms of borderline personality disorder. - 2026-07-01 — [Oryzon completes €12 million capital increase and signs conditional COFIDES subscription agreement](https://faqsir.com/company/oryzon-genomics-sa/oryzon-completes-eur12-million-capital-increase-and-signs-conditional-cofides-subscription-agreement): Oryzon Genomics issued 4,444,445 new shares at €2.70 each and entered an agreement for a potential future €25 million subscription by COFIDES's Social Impact Fund, subject to stated conditions. - 2026-06-11 — [Oryzon Reports Updated Iadademstat Data from AML Trials at EHA 2026](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-updated-iadademstat-data-from-aml-trials-at-eha-2026): Oryzon Genomics presented updated clinical findings from its ALICE-2 and FRIDA trials evaluating iadademstat in different acute myeloid leukemia settings. - 2026-06-02 — [Oryzon reports first patient enrolled in Phase II IDEAL trial for essential thrombocythemia](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-first-patient-enrolled-in-phase-ii-ideal-trial-for-essential-thrombocythemia): Oryzon Genomics has enrolled the first patient in IDEAL, a Phase II study assessing iadademstat in adults with essential thrombocythemia who are resistant or intolerant to hydroxyurea. - 2026-05-14 — [Oryzon reports first-quarter 2026 results as clinical programmes advance](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-first-quarter-2026-results-as-clinical-programmes-advance): Oryzon Genomics reported first-quarter 2026 financial results alongside updates on its oncology, haematology and CNS programmes, including ALICE-2, FRIDA and PORTICO-2. - 2026-05-13 — [Oryzon to Present Updated Iadademstat Data in Two AML Trials at EHA 2026](https://faqsir.com/company/oryzon-genomics-sa/oryzon-to-present-updated-iadademstat-data-in-two-aml-trials-at-eha-2026): Oryzon Genomics said updated findings from two Phase Ib trials of iadademstat in acute myeloid leukemia will be presented at the EHA Annual Congress in Stockholm. - 2026-03-25 — [Oryzon reports U.S. Notice of Allowance for vafidemstat patent application](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-us-notice-of-allowance-for-vafidemstat-patent-application): Oryzon Genomics said the USPTO issued a Notice of Allowance for a vafidemstat-related patent application covering non-aggressive symptoms of borderline personality disorder. - 2026-03-23 — [Oryzon reports U.S. patent grant for iadademstat and venetoclax combinations](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-us-patent-grant-for-iadademstat-and-venetoclax-combinations): Oryzon Genomics said the USPTO granted U.S. patent US12,564,559 B2 covering therapeutic combinations of iadademstat, including venetoclax, in neoplastic disease treatment. - 2026-03-12 — [Oryzon reports Mexican decision to grant patent for iadademstat combinations](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-mexican-decision-to-grant-patent-for-iadademstat-combinations): Oryzon Genomics has received a Mexican decision to grant a patent covering iadademstat combinations with PD-1 or PD-L1 inhibitors, including use in small cell lung cancer. - 2026-02-27 — [Oryzon reports 2025 results as clinical programmes advance](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-2025-results-as-clinical-programmes-advance): Oryzon Genomics reported its 2025 financial results, including $33.3 million in cash, cash equivalents and marketable securities, while providing updates across its oncology, haematology and CNS progr... - 2026-02-24 — [Oryzon receives EMA authorisation to begin Phase II iadademstat study in essential thrombocythemia](https://faqsir.com/company/oryzon-genomics-sa/oryzon-receives-ema-authorisation-to-begin-phase-ii-iadademstat-study-in-essential-thrombocythemia): Oryzon Genomics has received European Medicines Agency authorisation to initiate a Phase II study of iadademstat in adults with essential thrombocythemia who are resistant or intolerant to hydroxyurea... - 2026-02-12 — [Oryzon appoints Rolando Gutierrez-Esteinou as Chief Medical Officer for CNS programmes](https://faqsir.com/company/oryzon-genomics-sa/oryzon-appoints-rolando-gutierrez-esteinou-as-chief-medical-officer-for-cns-programmes): Oryzon Genomics has named Harvard-trained psychiatrist Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs, ahead of planned Phase III development for vafidemstat. - 2026-02-09 — [Oryzon reports first dosing in Yale-led Phase Ib iadademstat study for ES-SCLC](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-first-dosing-in-yale-led-phase-ib-iadademstat-study-for-es-sclc): Oryzon Genomics said the first patient has received treatment in an investigator-initiated Phase Ib study evaluating iadademstat alongside atezolizumab and stereotactic body radiation therapy in exten... - 2026-02-02 — [Oryzon receives Japanese patent grant decision for vafidemstat application](https://faqsir.com/company/oryzon-genomics-sa/oryzon-receives-japanese-patent-grant-decision-for-vafidemstat-application): Oryzon Genomics has received a Japanese Decision to grant for a vafidemstat patent application covering aggression and social withdrawal associated with CNS disorders. - 2025-12-22 — [Oryzon receives Japanese decision to grant iadademstat combination patent](https://faqsir.com/company/oryzon-genomics-sa/oryzon-receives-japanese-decision-to-grant-iadademstat-combination-patent): Oryzon Genomics said Japan’s patent office has issued a Decision to Grant for its iadademstat combination patent application, subject to formal grant. - 2025-12-15 — [Oryzon shareholders approve resolutions at December 2025 extraordinary meeting](https://faqsir.com/company/oryzon-genomics-sa/oryzon-shareholders-approve-resolutions-at-december-2025-extraordinary-meeting): Oryzon Genomics said shareholders approved all resolutions at its Extraordinary General Shareholders’ Meeting, with favorable votes ranging from 93% to 98%. - 2025-12-09 — [Oryzon reports updated iadademstat combination data in AML at ASH](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-updated-iadademstat-combination-data-in-aml-at-ash): Oryzon Genomics has reported updated findings from two ongoing Phase Ib studies evaluating iadademstat combinations in acute myeloid leukaemia. - 2025-11-07 — [Oryzon reports $4.6 million net loss for nine months ended September 30, 2025](https://faqsir.com/company/oryzon-genomics-sa/oryzon-reports-46-million-net-loss-for-nine-months-ended-september-30-2025): Oryzon Genomics reported financial results for the nine months ended September 30, 2025, alongside updates on its central nervous system and haematology programmes. - 2025-11-04 — [Oryzon says three iadademstat abstracts accepted for ASH 2025](https://faqsir.com/company/oryzon-genomics-sa/oryzon-says-three-iadademstat-abstracts-accepted-for-ash-2025): Oryzon Genomics said three abstracts involving iadademstat have been accepted for presentation at the 67th American Society of Hematology Annual Meeting in Orlando, Florida. - 2025-11-03 — [Oryzon enrols first patient in Phase Ib RESTORE trial of iadademstat for sickle cell disease](https://faqsir.com/company/oryzon-genomics-sa/oryzon-enrols-first-patient-in-phase-ib-restore-trial-of-iadademstat-for-sickle-cell-disease): Oryzon Genomics said the first patient has been enrolled in RESTORE, a Phase Ib study assessing iadademstat in adults with sickle cell disease. - 2025-10-28 — [Oryzon appoints Dr. Iman Barilero as Senior Advisor for Regulatory Affairs](https://faqsir.com/company/oryzon-genomics-sa/oryzon-appoints-dr-iman-barilero-as-senior-advisor-for-regulatory-affairs): Oryzon Genomics has appointed Dr. Iman Barilero as Senior Advisor for Regulatory Affairs to support its vafidemstat development programmes and wider CNS pipeline. - 2025-10-17 — [Oryzon receives FDA feedback on Phase III vafidemstat protocol for BPD](https://faqsir.com/company/oryzon-genomics-sa/oryzon-receives-fda-feedback-on-phase-iii-vafidemstat-protocol-for-bpd): Oryzon Genomics has received written FDA feedback on its proposed Phase III protocol for vafidemstat in borderline personality disorder and plans to revise and resubmit the document.